Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates

Alimera Sciences (ALIM) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -450%. A quarter ago, it was expected that this eye drug developer would post a loss of $0.41 per share when it actually produced a loss of $0.06, delivering a surprise of 85.37%.Over the last four quarters, the company has surpass ...